The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma
- PMID: 31796665
- PMCID: PMC7081094
- DOI: 10.3233/CBM-190904
The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma
Abstract
Background: Ovarian clear cell carcinoma (CCC) is enriched in genes associated with glucose metabolism.
Objective: To evaluate the 18F-FDG PET/CT-based metabolic variables and the correlations with clinicopathologic features in OCCC patients.
Methods: We measured quantitative parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG).
Results: A total of 22 patients were included. PET/CT-based metabolic parameters were calculated for 20 patients because two had low glucose-uptake tumor. The median SUVmax was 7.25 (range 2.50-14.80). Spearman's correlation test revealed that the level of pre-operative serum cancer antigen 125 (CA 125) correlated significantly with MTV (P= 0.020) and TLG (P= 0.023). Interestingly, platinum-sensitive patients tended to have higher MTV/TLG though significance not achieved. On univariate analysis, the following four variables (stage, residual disease, platinum sensitivity and MTV50) were significant for both progression-free survival and overall survival. Besides, four metabolic parameters (MTV40, TLG40, TLG50 and TLG60) were significantly associated with patients' overall survival. Out of expectation, ovarian CCC patients with higher level of MTV/TLG tended to have better survival.
Conclusions: 18F-FDG PET/CT-based metabolic volumetric parameters might be predicators for survival in ovarian CCC patients. Cautions should be taken when interpreting the results due to the small sample size.
Keywords: 18F-FDG PET/CT; Ovarian clear cell carcinoma; metabolic tumor volume; prognosis; total lesion glycolysis.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Similar articles
-
18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications.BMC Cancer. 2019 Mar 13;19(1):226. doi: 10.1186/s12885-019-5441-7. BMC Cancer. 2019. PMID: 30866858 Free PMC article.
-
Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125.Eur Radiol. 2022 Apr;32(4):2200-2208. doi: 10.1007/s00330-021-08305-x. Epub 2021 Sep 29. Eur Radiol. 2022. PMID: 34586465
-
The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1898-906. doi: 10.1007/s00259-014-2803-x. Epub 2014 May 23. Eur J Nucl Med Mol Imaging. 2014. PMID: 24852188
-
Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in ovarian cancer: a systematic review and meta-analysis.Ann Nucl Med. 2018 Dec;32(10):669-677. doi: 10.1007/s12149-018-1289-1. Epub 2018 Aug 12. Ann Nucl Med. 2018. PMID: 30101392
-
PET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous Disorders.PET Clin. 2022 Jul;17(3):465-478. doi: 10.1016/j.cpet.2022.03.006. PET Clin. 2022. PMID: 35717102 Review.
Cited by
-
Prognostic Value of Pretreatment 18F-FDG-PET/CT Metabolic Parameters in Advanced High-Grade Serous Ovarian Cancer.Cancers (Basel). 2025 Feb 19;17(4):698. doi: 10.3390/cancers17040698. Cancers (Basel). 2025. PMID: 40002291 Free PMC article.
-
Predicting epithelial ovarian cancer prognosis: correlation of posttreatment 18F-fluorodeoxyglucose positron emission tomography-computed tomography metabolic parameters, serum carbohydrate antigen, and human epididymis protein levels with overall survival.Quant Imaging Med Surg. 2024 Jan 3;14(1):972-985. doi: 10.21037/qims-23-859. Epub 2024 Jan 2. Quant Imaging Med Surg. 2024. PMID: 38223064 Free PMC article.
-
PET/CT Volumetric Parameters as Predictors of the Peritoneal Cancer Index in Advanced Ovarian Cancer Patients.Diagnostics (Basel). 2025 Jul 19;15(14):1818. doi: 10.3390/diagnostics15141818. Diagnostics (Basel). 2025. PMID: 40722567 Free PMC article.
References
-
- Anglesio M.S., Carey M.S., Kobel M., Mackay H. and Huntsman D.G., Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010, Gynecologic Oncology 121 (2011), 407–15. - PubMed
-
- del Carmen M.G., Birrer M. and Schorge J.O., Clear cell carcinoma of the ovary: A review of the literature, Gynecologic Oncology 126 (2012), 481–90. - PubMed
-
- Yamaguchi K., Mandai M., Oura T., Matsumura N., Hamanishi J., Baba T., Matsui S., Murphy S.K. and Konishi I., Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes, Oncogene 29 (2010), 1741–52. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials